| __timestamp | Iovance Biotherapeutics, Inc. | Merck & Co., Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 9335772 | 16768000000 |
| Thursday, January 1, 2015 | 999000 | 14934000000 |
| Friday, January 1, 2016 | 978000 | 13891000000 |
| Sunday, January 1, 2017 | 952000 | 12775000000 |
| Monday, January 1, 2018 | 956000 | 13509000000 |
| Tuesday, January 1, 2019 | 8122999 | 14112000000 |
| Wednesday, January 1, 2020 | 8712000 | 13618000000 |
| Friday, January 1, 2021 | 13980000 | 13626000000 |
| Saturday, January 1, 2022 | 21135000 | 17411000000 |
| Sunday, January 1, 2023 | 10755000 | 16126000000 |
Infusing magic into the data realm
In the ever-evolving pharmaceutical landscape, understanding cost structures is crucial. This analysis compares the cost of revenue for Merck & Co., Inc. and Iovance Biotherapeutics, Inc. from 2014 to 2023. Merck, a titan in the industry, consistently reported costs in the range of $13 billion to $17 billion annually. In contrast, Iovance, a burgeoning biotech firm, showed a more modest cost structure, peaking at approximately $21 million in 2022.
Merck's cost of revenue remained relatively stable, with a slight increase of about 4% from 2014 to 2023. Meanwhile, Iovance experienced a dramatic rise, with costs surging by over 100% from 2014 to 2022. This stark contrast highlights the differing scales and growth trajectories of these companies. As Merck maintains its stronghold, Iovance's increasing costs reflect its aggressive expansion and investment in innovative therapies.
Cost of Revenue Comparison: Eli Lilly and Company vs Merck & Co., Inc.
Cost of Revenue Trends: AbbVie Inc. vs Iovance Biotherapeutics, Inc.
Merck & Co., Inc. vs Regeneron Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Merck & Co., Inc. vs Teva Pharmaceutical Industries Limited: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Merck & Co., Inc. and Neurocrine Biosciences, Inc.
Cost of Revenue Comparison: Merck & Co., Inc. vs Xenon Pharmaceuticals Inc.
Cost Insights: Breaking Down Merck & Co., Inc. and Viridian Therapeutics, Inc.'s Expenses
Analyzing Cost of Revenue: Bristol-Myers Squibb Company and Iovance Biotherapeutics, Inc.
Takeda Pharmaceutical Company Limited vs Iovance Biotherapeutics, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: PTC Therapeutics, Inc. vs Iovance Biotherapeutics, Inc.
Agios Pharmaceuticals, Inc. vs Iovance Biotherapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Iovance Biotherapeutics, Inc. and Wave Life Sciences Ltd.